TECHNE CORPORATION AND SUBISIDARIES

TECHNE CORPORATION AND SUBSIDIARIES

(in thousands of $’s, except per share data)

	Fiscal 2006				Increase(Decrease) From Fiscal 2005
	First Quarter	Second Quarter	YTD	Percent Of Sales	First Quarter	Second Quarter	YTD
Sales	47,709	48,029	95,738	100%	6,790	5,782	12,572
Cost of sales	11,096	10,695	21,791	23%	2,209	1,754	3,963
Gross margin	36,613	37,334	73,947	77%	4,581	4,028	8,609

Gross margin percentage	76.7%	77.7%	77.2%

SG&A expense	6,454	7,980	14,434	15%	820	1,690	2,510
R&D expense	4,717	4,574	9,291	10%	29	(45)	(16)
Amortization expense	492	492	984	1%	187	186	373
Interest expense	223	238	461	--	(22)	60	38
Interest income	(974)	(1,130)	(2,104)	(2%)	79	59	138
Othernon-operating exp., net	211	281	492	--	(255)	(135)	(390)
	11,123	12,435	23,558	24%	838	1,815	2,653
Earnings before income taxes	25,490	24,899	50,389	53%	3,743	2,213	5,956
Income taxes	8,489	8,385	16,874	18%	934	633
	17,001	17,001	16,514	33,515	2,809	2,809	4,389

Diluted earnings per share	0.43	0.42	0.84
Weighted average diluted shares outstanding	39,669	39,761	39,730

HEMATOLOGY DIVISION

(in thousands of $’s)

	Fiscal 2006				Increase(Decrease) From Fiscal 2005
	First Quarter	Second Quarter	YTD	Percent Of Sales	First Quarter	Second Quarter	YTD
Sales	3,534	3,781	7,315	100%	(479)	(734)	(1,213)
Cost of sales	2,105	2,134	4,239	58%	(115)	(29)	(144)
Gross margin	1,429	1,647	3,076	42%	(364)	(705)	(1,069)

Gross margin percentage	40.4%	43.6%	42.1%

SG&A expense	384	424	808	11%	(25)	(12)	(37)
R&D expense	185	170	355	5%	(3)	(19)	(22)
Interest, net	(37)	(50)	(87)	(1%)	19	27	46
	532	544	1,076	15%	(9)	(4)	(13)
Pretax result	897	1,103	2,000	27%	(355)	(701)	(1,056)

BIOTECHNOLOGY DIVISION (1)

(in thousands of $’s)

	Fiscal 2006				Increase(Decrease) From Fiscal 2005
	First Quarter	Second Quarter	YTD	Percent Of Sales	First Quarter	Second Quarter	YTD
Sales	37,599	37,697	75,296	100%	6,908	7,625	14,533
Intersegment sales	(5,299)	(6,555)	(11,854)		(495)	(1,351)	(1,846)
	32,300	31,142	63,442		6,413	6,274	12,687

Cost of sales	8,470	8,147	16,617	22%	2,359	2,077	4,436
Intersegment sales	(5,323)	(6,140)	(11,463)		(567)	(930)	(1,497)
	3,147	2,007	5,154		1,792	1,147	2,939

Gross margin	29,153	29,135	58,288	78%	4,621	5,127	9,748

Gross margin percentage	77.5%	77.5%	78.4%	77.9%

SG&A expense	3,639	4,194	7,833	10%	666	779	1,445
R&D expense	4,532	4,404	8,936	12%	32	(26)	6
Amortization expense	492	492	984	1%	187	186	373
Interest, net	(268)	(373)	(641)	--	146	191
	8,395	8,717	17,112	23%	1,031	1,130	2,161
Pretax result	20,758	20,418	41,176	55%	3,590	3,997	7,587

(1) Fiscal 2006 includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

Back to Top

R&D SYSTEMS EUROPE

(in thousands of £'s)

	Fiscal 2006				Increase(Decrease) From Fiscal 2005
	First Quarter	Second Quarter	YTD	Percent Of Sales	First Quarter	Second Quarter	YTD
Sales	6,690	7,529	14,219	100%	610	721	1,331
Cost of sales	3,292	3,765	7,057	50%	361	632	993
Gross margin	3,398	3,764	7,162	50%	249	89	338

Gross margin percentage	50.8%	50.0%	50.4%

SG&A expense	1,004	1,185	2,189	15%	54	24	78
Interest income	(326)	(329)	(655)	(4%)	(72)	(66)	(138)
Exchange loss/(gain)	15	26	41	--	(11)	70	59
	693	882	1,575	11%	(29)	28	(1)
Pretax result	2,705	2,882	5,587	39%	278	61	339

R&D SYSTEMS EUROPE

(in thousands of $’s)

	Fiscal 2006				Increase(Decrease) From Fiscal 2005
	First Quarter	Second Quarter	YTD	Percent Of Sales	First Quarter	Second Quarter	YTD
Sales	11,875	13,106	24,981	100%	856	242	1,098
Cost of sales	5,844	6,554	12,398	50%	532	636	1,168
Gross margin	6,031	6,552	12,583	50%	324	(394)	(70)

Gross margin percentage	50.8%	50.8%	50.0%

SG&A expense	1,782	2,059	3,841	15%	60	(135)	(75)
Interest income	(579)	(572)	(1,151)	(4%)	(119)	(75)	(194)
Exchange loss	28	46	74	--	(19)	128	109
	1,231	1,533	2,764	11%	(78)	(82)	(160)
Pretax result	4,800	5,019	9,819	39%	402	(312)	90

CORPORATE AND OTHER (2)

(in thousands of $’s)

	Fiscal 2005			Increase(Decrease) From Fiscal 2005
	First Quarter	Second Quarter	YTD	First Quarter	Second Quarter	YTD
Interest income	90	135	225	48	84	132
Rental income	342	337	679	323	284	607
	432	472	904	371	368	739

SG&A expense	649	1,303	1,952	119	1,058	1,177
Interest expense	223	238	461	59	60	119
Other-Hemerus losses	82	82	164	79	12	91
Other-Building expenses	443	490	933	8	9	17
	1,397	2,113	3,510	265	1,139	1,404
Pretax result	(965)	(1,641)	(2,606)	106	(771)	(665)